Partnership opportunities

Hudson Institute has a focus on the translation of our research to deliver health benefits to the community.

We have a number of opportunities available for collaboration, investment, and licensing, to enable the development and commercialisation of our research and technologies.

Below are examples of technologies developed by Hudson Institute researchers. Contact us if you are interested in these, or if you have specific area you would like to pursue.

Exosome therapy – a cell-free approach to regenerative medicineIn partnership with Monash University, our researchers are developing the use of exosomes as treatment for idiopathic pulmonary fibrosis, through our spin-out company Regenasome Pty Ltd.
Wound healing and skin repairHudson researchers have identified unique factors that promote the healing of skin, by promoting cellular adhesion and migration of skin cells to the site needing repair.
Novel immunotherapy for ovarian cancerFollowing their discovery of IFNε, our researchers have found it has distinct properties that position it as a potential novel therapeutic for ovarian cancer.
Improving IVF outcomes: Assessing endometrial receptivityOur team has developed a serum-based diagnostic predictive of endometrial receptivity in the days prior to an embryo transfer, providing a real-time assessment of the endometrial quality so clinicians and patients can make informed decisions about treatment.
SRY inhibition to treat Parkinson’s disease in menOur researchers are developing a novel targeted antisense oligonucleotide therapy for men with Parkinson’s disease, through our spin-out company XYnapse Therapeutics Pty Ltd.
Production of inhibin analogs: Generating potentialThe protein inhibin has potential as both a research tool and novel therapeutic, but challenges in producing it at scale have hindered its development. Our researchers have produced a series of inhibin analogs that overcome these issues.
Screening marker for early-onset preeclampsiaHudson researchers have identified a novel biomarker for early-onset preeclampsia that is expressed before other symptoms are visible.
Development of therapeutics for preeclampsiaOur researchers have identified a molecule linked to preeclampsia development in women. This molecule represents a novel target for the development of urgently needed therapeutics for this disease.
Small molecule inhibitors of liver receptor homolog-1 (LRH-1)In partnership with St Vincent’s Institute, our researchers have identified a lead series inhibiting LRH-1, aberrant expression of which is associated with a range of cancers.
Spiny mouse (Acomys cahirinus): First menstruating rodentHudson Institute researchers have developed the first non-primate animal model that can be used to study menstruation and associated disorders.
Mouse model of preeclampsiaOur scientists have developed a unique in vivo model that recapitulates the main features of human preeclampsia.


For more information on any of our projects, contact Rob Merriel, Chief Commercialisation Officer.

R&D opportunities are also available, and Hudson Institute is a registered Research Service Provider.